1. Home
  2. CINGW vs CTRN Comparison

CINGW vs CTRN Comparison

Compare CINGW & CTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • CTRN
  • Stock Information
  • Founded
  • CINGW N/A
  • CTRN 1946
  • Country
  • CINGW United States
  • CTRN United States
  • Employees
  • CINGW 13
  • CTRN N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • CTRN Clothing/Shoe/Accessory Stores
  • Sector
  • CINGW Health Care
  • CTRN Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • CTRN Nasdaq
  • Market Cap
  • CINGW N/A
  • CTRN N/A
  • IPO Year
  • CINGW 2021
  • CTRN 2005
  • Fundamental
  • Price
  • CINGW $0.04
  • CTRN $25.41
  • Analyst Decision
  • CINGW
  • CTRN Strong Buy
  • Analyst Count
  • CINGW 0
  • CTRN 3
  • Target Price
  • CINGW N/A
  • CTRN $27.67
  • AVG Volume (30 Days)
  • CINGW N/A
  • CTRN 87.5K
  • Earning Date
  • CINGW N/A
  • CTRN 03-18-2025
  • Dividend Yield
  • CINGW N/A
  • CTRN N/A
  • EPS Growth
  • CINGW N/A
  • CTRN N/A
  • EPS
  • CINGW N/A
  • CTRN N/A
  • Revenue
  • CINGW N/A
  • CTRN $757,086,000.00
  • Revenue This Year
  • CINGW N/A
  • CTRN $2.46
  • Revenue Next Year
  • CINGW N/A
  • CTRN $3.77
  • P/E Ratio
  • CINGW N/A
  • CTRN N/A
  • Revenue Growth
  • CINGW N/A
  • CTRN 2.00
  • 52 Week Low
  • CINGW N/A
  • CTRN $13.66
  • 52 Week High
  • CINGW N/A
  • CTRN $32.90
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • CTRN 45.06
  • Support Level
  • CINGW N/A
  • CTRN $27.08
  • Resistance Level
  • CINGW N/A
  • CTRN $29.02
  • Average True Range (ATR)
  • CINGW 0.00
  • CTRN 1.31
  • MACD
  • CINGW 0.00
  • CTRN -0.03
  • Stochastic Oscillator
  • CINGW 0.00
  • CTRN 39.30

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: